Ceramide and Related-Sphingolipid Levels Are Not Altered in Disease-Associated Brain Regions of APPSL and APPSL/PS1M146L Mouse Models of Alzheimer's Disease: Relationship with the Lack of Neurodegeneration?
There is evidence linking sphingolipid abnormalities, APP processing, and neuronal death in Alzheimer's disease (AD). We previously reported a strong elevation of ceramide levels in the brain of the APPSL/PS1Ki mouse model of AD, preceding the neuronal death. To extend these findings, we analy...
Main Authors: | Laurence Barrier, Bernard Fauconneau, Anastasia Noël, Sabrina Ingrand |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2011-01-01
|
Series: | International Journal of Alzheimer's Disease |
Online Access: | http://dx.doi.org/10.4061/2011/920958 |
Similar Items
-
Decreased plasma Aβ in hyperlipidemic APPSL transgenic mice is associated with BBB dysfunction
by: Tina eLöffler, et al.
Published: (2016-06-01) -
Apoptotic Sphingolipid Ceramide in Cancer Therapy
by: Wei-Ching Huang, et al.
Published: (2011-01-01) -
Novelty of Sphingolipids in the Central Nervous System Physiology and Disease: Focusing on the Sphingolipid Hypothesis of Neuroinflammation and Neurodegeneration
by: Maria Ayub, et al.
Published: (2021-07-01) -
Sphingolipid and Ceramide Homeostasis: Potential Therapeutic Targets
by: Simon A. Young, et al.
Published: (2012-01-01) -
Exploring Sphingolipid Implications in Neurodegeneration
by: Alice V. Alessenko, et al.
Published: (2020-05-01)